Modeling Tumor Evolution in Glioma
神经胶质瘤的肿瘤进化建模
基本信息
- 批准号:10019611
- 负责人:
- 金额:$ 18.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-30 至 2021-08-31
- 项目状态:已结题
- 来源:
- 关键词:19qAffectAftercareAneuploidyAntibody-drug conjugatesAppearanceAutomobile DrivingBiological ModelsCDK4 geneCDKN2A geneCell CycleCellsChemotherapy and/or radiationChromosome ArmChromosome SegregationClinical TrialsCollectionCommunitiesComplexComputer AnalysisCountryDNA sequencingDataData AnalysesData PoolingData SetDatabasesDefectDiagnosisDiffuseDiseaseEpidermal Growth Factor ReceptorEventEvolutionFundingFutureGene AbnormalityGenetic TranscriptionGenomicsGliomaGoalsGrowth and Development functionHospitalsImmuneImmune EvasionImmune responseImmune systemImmunologic SurveillanceImmunotherapyInfiltrative GrowthInfrastructureInstitutionInternationalInvestigationLaboratoriesMagnetic Resonance ImagingMalignant NeoplasmsMindMitotic spindleModelingMolecularMolecular ProfilingMutationOperative Surgical ProceduresOutcomePDGFRA genePathologyPathway interactionsPatientsPatternPortraitsPositioning AttributePrimary NeoplasmProcessPropertyProtocols documentationQuality of lifeRB1 geneReceptor Protein-Tyrosine KinasesRecurrenceRecurrent tumorRegimenResearch InstituteResistanceResistance developmentResourcesSamplingScientistSiteSourceSpecimenStandardizationTestingThe Cancer Genome AtlasTherapeutic InterventionTimeTissuesTreatment outcomeTumor DebulkingTumor-Associated ProcessUniversitiesWorkbasecancer typecdc Genescohortcomputerized data processingdata standardsdosageeffective therapyexperimental studyimmunogenicin vivo Modelinsightlongitudinal analysislongitudinal datasetmolecular subtypesmultidimensional datamutantneoantigensneoplastic cellnoveloutcome forecastpatient variabilityphenotypic dataresponsetherapy developmenttherapy resistanttooltreatment effecttreatment responsetreatment strategytumortumor heterogeneity
项目摘要
PROJECT SUMMARY
Treatment of patients with glioma has been largely unsuccessful, and even if initial treatment shows some
effect, the long-term prognosis remains poor because recurrence of the disease is near-certain. A significant
challenge in establishing treatments for recurrent gliomas is that the diffuse infiltrative growth and presumed
extensive tumor heterogeneity allows tumor cells to “escape” and even develop resistance to therapy. In order
for better treatments to be developed we need to understand both the extent of tumor heterogeneity and how it
evolves in response to treatment. Although such a need is easily stated it has been difficult, if not impossible,
to achieve with current resources because it requires tracking and characterizing tumor changes within the
same patient. Moreover, because of patient to patient variability, and the need for statistical power, these
types of investigations also require standardized data from hundreds of patients.
With these requirements in mind, and the long-term goal of identifying new, effective treatment targets, we
initiated the international Glioma Longitudinal Analysis (GLASS) Consortium. Since 2014, GLASS has
established the largest (and still expanding) database of tumor samples sequenced at different time points
among any cancer type. Data from these samples (collected at 34 institutions in 12 countries) are now
aggregated and integrated with patient and phenotypic data across international sub studies. The GLASS
dataset is supported by an infrastructure that standardizes key parameters across studies/sites so that
complex, integrated analyses are possible. Preliminary analysis of this unique dataset demonstrated that it will
allow us to create a portrait of the recurrence process and discover novel molecular vulnerabilities that can be
targeted for successful therapeutic intervention.
We are now poised to further exploit the GLASS data to identify critical processes driving glioma evolution. To
do this we propose: Aim1 - To test the hypothesis that clonal diversity (tumor heterogeneity) is significantly
impacted by treatment, and Aim 2 - To test the hypothesis that immunoediting results in the selection of glioma
cells that are capable of evading the immune response.
Upon completion of these aims, we will have gained new insights into how treatment and the immune system
drive the clonal (tumor cell) selection that leads to glioma tumor heterogeneity. In the process, we will also
establish and share the tools/approaches needed for valid analyses of this type of multi-dimensional, multi-time
point data. Taken together, the results of these efforts should identify novel avenues for treatment with better,
more reliable outcomes.
项目概要
神经胶质瘤患者的治疗基本上不成功,即使初步治疗显示出一些效果
效果,长期预后仍然很差,因为疾病复发几乎是肯定的。一个重要的
建立复发性神经胶质瘤治疗方法的挑战在于,弥漫性浸润性生长和推测的
广泛的肿瘤异质性使得肿瘤细胞能够“逃脱”,甚至对治疗产生耐药性。为了
为了开发更好的治疗方法,我们需要了解肿瘤异质性的程度以及它是如何发生的。
随着治疗的反应而发展。尽管这种需求很容易表达,但即使不是不可能,也是很困难的,
利用现有资源来实现,因为它需要跟踪和描述肿瘤变化的特征
同一个病人。此外,由于患者之间的差异以及对统计功效的需要,这些
各种类型的调查还需要来自数百名患者的标准化数据。
考虑到这些要求以及确定新的、有效的治疗目标的长期目标,我们
发起了国际胶质瘤纵向分析(GLASS)联盟。自 2014 年以来,GLASS 已
建立了最大(且仍在扩展)的不同时间点测序肿瘤样本数据库
任何癌症类型中。这些样本的数据(从 12 个国家的 34 个机构收集)现已公布
汇总并整合国际子研究中的患者和表型数据。玻璃
数据集由基础设施支持,该基础设施标准化了研究/站点的关键参数,以便
复杂的综合分析是可能的。对这个独特数据集的初步分析表明,它将
让我们能够描绘复发过程并发现新的分子漏洞
以成功的治疗干预为目标。
我们现在准备进一步利用 GLASS 数据来识别驱动神经胶质瘤进化的关键过程。到
为此,我们建议: 目标 1 - 检验克隆多样性(肿瘤异质性)显着的假设
受治疗的影响,目标 2 - 检验免疫编辑导致神经胶质瘤选择的假设
能够逃避免疫反应的细胞。
完成这些目标后,我们将对治疗和免疫系统如何产生新的见解
驱动导致神经胶质瘤肿瘤异质性的克隆(肿瘤细胞)选择。在此过程中,我们还将
建立并分享有效分析此类多维、多时间所需的工具/方法
点数据。总而言之,这些努力的结果应该能够找到新的治疗途径,提供更好、更有效的治疗方法。
更可靠的结果。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Roel GW Verhaak其他文献
Roel GW Verhaak的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Roel GW Verhaak', 18)}}的其他基金
Characterization of extrachromosomal DNAs in tumors through computational analysis of single-cell and bulk sequencing data
通过单细胞和批量测序数据的计算分析来表征肿瘤中的染色体外 DNA
- 批准号:
10302738 - 财政年份:2021
- 资助金额:
$ 18.9万 - 项目类别:
Characterization of extrachromosomal DNAs in tumors through computational analysis of single-cell and bulk sequencing data
通过单细胞和批量测序数据的计算分析来表征肿瘤中的染色体外 DNA
- 批准号:
10810168 - 财政年份:2021
- 资助金额:
$ 18.9万 - 项目类别:
Advancing Ultra Long-read Sequencing and Chromatin Interaction Analyses for Chromosomal and Extrachromosomal Structural Variation Characterization in Cancer
推进超长读长测序和染色质相互作用分析,用于癌症染色体和染色体外结构变异表征
- 批准号:
9889550 - 财政年份:2020
- 资助金额:
$ 18.9万 - 项目类别:
Extrachromosomal DNA as a Targetable Mechanism in Glioblastoma
染色体外 DNA 作为胶质母细胞瘤的靶向机制
- 批准号:
10296662 - 财政年份:2019
- 资助金额:
$ 18.9万 - 项目类别:
Extrachromosomal DNA as a Targetable Mechanism in Glioblastoma
染色体外 DNA 作为胶质母细胞瘤的靶向机制
- 批准号:
10807691 - 财政年份:2019
- 资助金额:
$ 18.9万 - 项目类别:
Extrachromosomal DNA as a Targetable Mechanism in Glioblastoma
染色体外 DNA 作为胶质母细胞瘤的靶向机制
- 批准号:
10533330 - 财政年份:2019
- 资助金额:
$ 18.9万 - 项目类别:
Extrachromosomal DNA as a Targetable Mechanism in Glioblastoma
染色体外 DNA 作为胶质母细胞瘤的靶向机制
- 批准号:
9887225 - 财政年份:2019
- 资助金额:
$ 18.9万 - 项目类别:
Extrachromosomal DNA as a Targetable Mechanism in Glioblastoma
染色体外 DNA 作为胶质母细胞瘤的靶向机制
- 批准号:
10063975 - 财政年份:2019
- 资助金额:
$ 18.9万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 18.9万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 18.9万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 18.9万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 18.9万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 18.9万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 18.9万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 18.9万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 18.9万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 18.9万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 18.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists














{{item.name}}会员




